NYHA Class IV Approval: In August 2024, scPharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval for FUROSCIX, expanding the indication to include New York Heart ...
"Lower gas prices were the biggest piece of good news again in the October CPI report. In the other direction, shelter inflation was sticky and unchanged in year-over-year terms," Bill Adams, chief ...
Nasdaq CEO Adena Friedman has a three-word piece of money advice for anyone who finds the investment market daunting. It’s ...
FTQI employs a buy-write strategy on the NASDAQ-100, aiming for a high yield of 12% through monthly distributions. FTQI's ...
(MENAFN- GlobeNewsWire - Nasdaq) Delray Beach, FL ... this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account ...
Q3 2024 ReportResults in line for Q3 2024 with sales momentum increasing throughout the period and into Q4GIG Software Plc ...
Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback